Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers. The medicine, a monoclonal antibody, would stimulate the immune system to attack the protein–killing the tumors.

Alzheimer's Association. Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research. Falls Church, VA: The Lewin Group; 2004

Reference

Title
Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research
Publisher
The Lewin Group
Publication Date
2004
Authors
Alzheimer's Association

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.  
  • A drug for testicular cancer that cost an estimated $56 million to develop led to a sharp increase in survival rate and an annual return of $166 million in treatment…  
  • Death rates from breast cancer have steadily decreased in women since 1990. This decrease represents progress in both early detection and improved treatment.  
  • Decline in Cancer Death Rates in Men
     
  • “Among women age 65 and over, the percentage who had a mammogram within the preceding 2 years almost tripled from 23% in 1987 to 64% in 2005.”